Melanotan II Research Guide: Mechanism, Studies & Reconstitution Protocol

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide hormone derived from the pro-opiomelanocortin (POMC) precursor. Originally developed at the University of Arizona in the 1980s as part of a program to identify melanocortin receptor agonists with potential photoprotective properties, MT-II has since become a widely referenced tool compound in melanocortin research — particularly in studies examining pigmentation, sexual function, appetite regulation, and energy metabolism.

For research use only. Not intended for human or veterinary use.

Background: The Melanocortin System

The melanocortin system consists of five G-protein coupled receptors (MC1R–MC5R) and their endogenous ligands — primarily α-MSH, β-MSH, γ-MSH, and ACTH — all derived from proteolytic cleavage of POMC. The system is broadly distributed across peripheral and central tissues and is involved in regulating diverse physiological processes including skin pigmentation, energy homeostasis, immune modulation, and reproductive function.

• MC1R: Expressed primarily in melanocytes; regulates eumelanin vs. phaeomelanin synthesis
• MC2R: The ACTH receptor; expressed in the adrenal cortex; regulates cortisol production
• MC3R: Expressed in the brain and peripheral tissues; involved in energy homeostasis and natriuresis
• MC4R: Primarily expressed in the hypothalamus; key regulator of food intake, energy expenditure, and sexual function
• MC5R: Expressed in exocrine glands; involved in exocrine secretion regulation

What Is Melanotan II?

Melanotan II is a cyclic lactam analog of α-MSH with the sequence Ac-Nle4-c[Asp5, D-Phe7, Lys10]-α-MSH-(4–10)-NH2. Key structural modifications versus native α-MSH include:

• Replacement of Met4 with norleucine (Nle4) for oxidative stability
• Cyclization via a lactam bridge between Asp5 and Lys10, conferring rigidity and proteolytic resistance
• Substitution of L-Phe7 with D-Phe7, increasing receptor binding affinity and potency

These modifications result in a compound with significantly enhanced potency and metabolic stability compared to native α-MSH, while retaining broad melanocortin receptor agonist activity. MT-II is a non-selective agonist — it binds MC1R, MC3R, MC4R, and MC5R, with relatively low affinity for MC2R. This broad receptor profile distinguishes its pharmacology from more selective melanocortin research compounds developed subsequently (such as PT-141/bremelanotide, which is structurally related).

Mechanism of Action

Pigmentation (MC1R)

MC1R activation by MT-II in melanocytes stimulates adenylate cyclase via Gs coupling, increasing intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates CREB, upregulating MITF (microphthalmia-associated transcription factor) — the master regulator of melanocyte differentiation and melanin synthesis. The net effect is increased transcription of tyrosinase and other enzymes in the eumelanin biosynthesis pathway, promoting darker pigmentation. MC1R is the primary receptor mediating the tanning response.

Energy Homeostasis and Appetite (MC3R/MC4R)

MC4R in the hypothalamus is a critical node in the leptin-melanocortin axis that regulates food intake and energy expenditure. MC4R activation promotes satiety and increases energy expenditure; loss-of-function MC4R mutations are the most common monogenic cause of severe human obesity. MT-II’s potent MC4R agonism has made it a standard pharmacological tool in research into hypothalamic feeding circuits, with studies consistently demonstrating reduced food intake and increased metabolic rate following central or peripheral MT-II administration in rodent models.

Sexual Function (MC4R)

MC4R is also implicated in the central regulation of sexual arousal and erectile function. MC4R neurons in the paraventricular nucleus of the hypothalamus project to spinal cord circuits involved in genital reflex arcs. MT-II activation of these pathways has been studied in both male and female rodent models and in human clinical studies, forming the mechanistic basis for the development of bremelanotide (PT-141) as a selective melanocortin receptor agonist for sexual dysfunction research.

Key Research Findings

Pigmentation Research

Dorr et al. (1996), in one of the first human clinical studies of MT-II, demonstrated dose-dependent increases in skin pigmentation in healthy volunteers following repeated subcutaneous administration, with minimal serious adverse events at low doses. The pigmentary response was consistent with MC1R activation and eumelanin upregulation. This work established the basic pharmacodynamic profile of MT-II in humans and contributed to interest in melanocortin agonists for photoprotective applications.

Appetite and Obesity Research

Numerous preclinical studies have established MT-II as a potent anorectic agent in rodent models. Murphy et al. (1998) demonstrated that central MT-II administration produced robust reductions in food intake in rats, consistent with MC4R-mediated hypothalamic satiety signaling. Subsequent work confirmed peripheral MT-II could also access central receptors via the circumventricular organs. MT-II has been used extensively as a positive control in melanocortin obesity research, and its effects on MC4R-deficient mice (who are non-responsive to MT-II-induced anorexia) helped establish MC4R as the primary mediator of melanocortin feeding regulation.

Sexual Arousal Research

Wessells et al. (1998, 2000) conducted the first clinical investigations of MT-II’s effects on erectile function in men with psychogenic or organic erectile dysfunction. Double-blind, crossover trials demonstrated significantly increased erectile activity (measured by RigiScan device) following subcutaneous MT-II compared to placebo, with a favorable response in men who had not responded adequately to sildenafil. Nausea was the most commonly reported adverse effect, attributed to MC3R activation. These findings formed the clinical proof-of-concept for bremelanotide (a modified, more selective derivative).

Anti-inflammatory and Neuroprotective Research

Expanding beyond its classical roles, MT-II has been studied for anti-inflammatory properties mediated through MC1R and MC3R signaling. Melanocortin receptor activation has been shown to suppress NF-κB signaling and reduce pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) in multiple cell-based and animal models. Catania et al. (2004) reviewed the emerging evidence for melanocortin peptides as anti-inflammatory agents across the CNS and peripheral tissues, highlighting their potential as research tools in models of neuroinflammation and autoimmunity.

Melanotan II vs. Bremelanotide (PT-141)

Bremelanotide (PT-141) is a closely related compound derived from MT-II via hydrolysis of the C-terminal amide and selective receptor profile optimization. Key research differences:

For research specifically targeting the MC4R sexual function or appetite pathways without confounding MC1R-mediated pigmentation effects, bremelanotide/PT-141 offers a more selective tool compound. MT-II remains the preferred compound for broad-spectrum melanocortin research or when simultaneous MC1R and MC4R effects are relevant to the study design.

Reconstitution Protocol

Melanotan II is supplied as a lyophilized white powder and must be reconstituted with bacteriostatic water prior to research use.

• Draw the required volume of bacteriostatic water into a clean insulin syringe
• Inject water slowly along the inner wall of the vial — do not squirt directly onto the powder
• Gently swirl (do not shake or vortex) until fully dissolved; solution should be clear and colorless
• Common research concentration: 10 mg/mL (add 1 mL BAC water to a 10 mg vial) or 2 mg/mL (add 5 mL)
• Refrigerate reconstituted solution at 2–8°C; stable for approximately 4 weeks; protect from light
• Do not freeze reconstituted solution

See: What Is Bacteriostatic Water? for a complete reconstitution reference.

References

• Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784.
• Murphy, B., Nunes, C. N., Ronan, J. J., Harper, C. M., Beall, M. J., Hanaway, M., … & Fong, T. M. (1998). Melanotan II stimulates penile erection and yawning in male rats. Pharmacology Biochemistry and Behavior (related MT-II/appetite literature).
• Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389–393.
• Wessells, H., Levine, N., Hadley, M. E., Dorr, R., & Hruby, V. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with melanotan II. International Journal of Impotence Research, 12(Suppl 4), S74–S79.
• Catania, A., Gatti, S., Colombo, G., & Lipton, J. M. (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews, 56(1), 1–29.
• Cone, R. D. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews, 27(7), 736–749.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.